<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25378" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Muscarinic Agonists</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bui</surname>
            <given-names>Toai</given-names>
          </name>
          <aff>SGMC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Duong</surname>
            <given-names>Hieu</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Toai Bui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hieu Duong declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25378.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Muscarinic agonists are parasympathomimetic drugs and are indicated for ileus, urinary retention, glaucoma, Alzheimer disease, and other symptoms. This activity describes the indications, contraindications, and possible adverse effects of muscarinic agonists and how the interprofessional team can work together to improve outcomes using these agents. This activity will also highlight the different mechanisms of action of different muscarinic receptors in different parts of the body.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of muscarinic agonists.</p></list-item><list-item><p>Describe the potential adverse effects of muscarinic agonists.</p></list-item><list-item><p>Outline the appropriate monitoring for muscarinic agonists.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance muscarinic agonists and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25378&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25378">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25378.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Muscarinic receptors are primarily on the postsynaptic cell membrane of smooth muscle, cardiac muscle, and exocrine gland cells. Muscarinic receptors are activated by acetylcholine and increase the activity of the parasympathetic nervous system. Muscarinic agonists mimic the action of acetylcholine on muscarinic receptors and cause cardiac slowing, contraction of smooth muscles (intestinal tract, bronchioles, detrusor muscle, urethra, and iris muscle), and increased secretion from exocrine glandular tissues (salivary, gastric acid, and airway mucosal gland). Muscarinic agonist has different indications depending on how potent and selective each agonist is.</p>
        <p>Muscarinic agonists divide into two groups: direct agonist and indirect agonist. Direct agonists resist acetylcholinesterase, thus preventing its breakdown. Indirect agonists work by inhibiting the acetylcholinesterase enzyme preventing the degradation of acetylcholine. Direct and indirect agonists both increase acetylcholine concentration in the synapse, prolonging&#x000a0;acetylcholine effects on the receptor.&#x000a0;</p>
        <p>
<bold>Direct Agonists</bold>
</p>
        <p>Bethanechol's indications include postoperative ileus, neurogenic ileus, and urinary retention.&#x000a0;Bethanechol&#x000a0;increases the smooth muscle tone of the gastrointestinal tract to&#x000a0;promote motility and restores peristalsis in the absence of obstruction. Bethanechol also increases the tone of the detrusor muscle to increase bladder emptying.<xref ref-type="bibr" rid="article-25378.r1">[1]</xref><xref ref-type="bibr" rid="article-25378.r2">[2]</xref></p>
        <p>Carbachol is indicated to treat open-angle glaucoma, acute angle-closure glaucoma, and increased intraocular pressure. Carbachol contracts the ciliary body muscle and opens the trabecular meshwork. Opening the meshwork increases aqueous humor outflow from the eye to reduce intraocular pressure.<xref ref-type="bibr" rid="article-25378.r3">[3]</xref>&#x000a0;</p>
        <p>Pilocarpine is indicated for open-angle glaucoma, acute angle-closure glaucoma, and ocular hypertension. When given topically, pilocarpine contracts the ciliary body muscle and opens the trabecular meshwork to increase the outflow of aqueous humor. Oral pilocarpine can be used to increase secretion of the salivary glands to treat dry mouth in patients with Sjogren's syndrome or salivary gland dysfunction.<xref ref-type="bibr" rid="article-25378.r4">[4]</xref><xref ref-type="bibr" rid="article-25378.r5">[5]</xref></p>
        <p>Methacholine is most commonly used to diagnose asthma or bronchial hyperactivity. Methacholine stimulates the muscarinic receptor in the airway when inhaled and induces bronchoconstriction, and increases tracheobronchial secretions. The lower the dose it takes for methacholine to induce bronchoconstriction, the more reactive the bronchial airway is.<xref ref-type="bibr" rid="article-25378.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>Indirect Agonists (Cholinesterase Inhibitors)</bold>
</p>
        <p>Neostigmine is indicated for postoperative and neurogenic ileus, urinary retention, myasthenia gravis, and reversal of neuromuscular junction blockade.<xref ref-type="bibr" rid="article-25378.r7">[7]</xref></p>
        <p>Physostigmine indications include glaucoma and anticholinergic toxicity, such as atropine overdose.<xref ref-type="bibr" rid="article-25378.r8">[8]</xref>&#x000a0;</p>
        <p>Galantamine, donepezil, and rivastigmine are indicated for Alzheimer disease. The medications help with memory loss as well as decrease plaque build-up. Galantamine, donepezil, and rivastigmine do not cure Alzheimer disease and can only delay the progression of the disease.<xref ref-type="bibr" rid="article-25378.r9">[9]</xref><xref ref-type="bibr" rid="article-25378.r10">[10]</xref></p>
        <p>The indirect agonists listed below have indications that&#x000a0;that require activity&#x000a0;on nicotinic receptors of the skeletal muscle rather than muscarinic receptors.</p>
        <p>Edrophonium is a short and rapid-acting anticholinesterase commonly used to evaluate and diagnose patients with myasthenia gravis.<xref ref-type="bibr" rid="article-25378.r11">[11]</xref>&#x000a0;</p>
        <p>Pyridostigmine is indicated for the treatment of myasthenia gravis.<xref ref-type="bibr" rid="article-25378.r12">[12]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25378.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Muscarinic agonists are agents that activate the muscarinic acetylcholine receptor. There are five different muscarinic receptors labeled M1-M5. Muscarinic agonists are parasympathomimetics, and their mechanism of action is different depending on which receptor is activated.&#x000a0;</p>
        <p>The M1, M3, and M5 are transmembrane receptors that couple to a Gq protein. The Gq protein upregulates phospholipase C (PLC). PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into 1,2- diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG activates protein kinase C, which activates downstream protein and causes calcium influx. IP3 causes the sarcoplasmic reticulum to release stored calcium. Increased intracellular calcium causes smooth muscle contraction and exocrine glandular secretions.<xref ref-type="bibr" rid="article-25378.r13">[13]</xref><xref ref-type="bibr" rid="article-25378.r14">[14]</xref>&#x000a0; &#x000a0;</p>
        <p>The M2 and M4 receptors are Gi receptor, which inhibits adenylyl cyclase. Inhibition of adenylyl cyclase decreases cyclic adenosine 3&#x02019;,5&#x02019;-monophosphate (cAMP) production from ATP. The decrease in cAMP concentration subsequently decreases the activation of protein kinase A.<xref ref-type="bibr" rid="article-25378.r15">[15]</xref><xref ref-type="bibr" rid="article-25378.r16">[16]</xref></p>
        <p>The clinically significant muscarinic receptors are the M1, M2, and M3 receptors.</p>
        <p>The M1 muscarinic receptor&#x000a0;is clinically significant&#x000a0;in the central nervous system, and it influences neurologic functions. Muscarinic agonists play an important role in the treatment of Alzheimer disease(AD). Memory loss in Alzheimer disease patients is associated with a cholinergic deficit due to the reduced activity of choline acetyltransferase, which synthesizes acetylcholine. Another important feature of AD is the accumulation of amyloid plaques and neurofibrillary tangles. Amyloid plaques are aggregates of amyloid-beta derived from cleaving amyloid precursor protein. Muscarinic agonists appear to increase the activity of a protease enzyme that cleaves amyloid precursor protein in such a manner that there is no production of amyloid-beta. Through such mechanisms, muscarinic agonists treat memory deficit and amyloid deposition in AD.<xref ref-type="bibr" rid="article-25378.r17">[17]</xref><xref ref-type="bibr" rid="article-25378.r18">[18]</xref></p>
        <p>The M2 muscarinic receptor is the predominant receptor found in the sinoatrial and atrioventricular nodal cells of the heart. The downstream effect, once the M2 receptor is activated, allows potassium efflux. Potassium efflux results in hyperpolarization and reduction of the action potential duration in the nodal cells. Therefore, the activation of the M2 receptor in the heart causes decreased heart rate and atrial contractility.<xref ref-type="bibr" rid="article-25378.r19">[19]</xref>&#x000a0;</p>
        <p>The M3 muscarinic receptor is&#x000a0;clinically significant&#x000a0;in the intestine's smooth muscle, bladder, airway, eye, exocrine glands, and blood vessels. Smooth muscle of the intestine, bladder, airway, and eye contracts when calcium concentration increase within the cell. Calcium binds with calmodulin to form a complex that can now activate the enzyme myosin light chain kinase. Myosin light chain kinase phosphorylates myosin resulting in contraction. Muscarinic agonists'&#x000a0;action on&#x000a0;blood vessels results in vasodilatation rather than vasoconstriction. Calcium in the endothelial cells activates nitric oxide synthase, converting L-arginine into nitric oxide. Nitric oxide diffuses into the underlying smooth muscle causing an increase in cGMP. cGMP activates myosin light chain phosphatase resulting in smooth muscle relaxation. When the endothelium is damaged, it does not produce nitric oxide and acetylcholine results in smooth muscle contraction.<xref ref-type="bibr" rid="article-25378.r20">[20]</xref><xref ref-type="bibr" rid="article-25378.r21">[21]</xref></p>
      </sec>
      <sec id="article-25378.s4" sec-type="Administration">
        <title>Administration</title>
        <list list-type="bullet">
          <list-item>
            <p>Bethanechol is administered orally on an empty stomach two to four times a day to prevent stomach upset and nausea.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Carbachol is commonly administered topically ocularly.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pilocarpine is administered topically, ocularly, or orally.</p>
          </list-item>
          <list-item>
            <p>Methacholine is administered through inhalation.</p>
          </list-item>
          <list-item>
            <p>Neostigmine is administered through intramuscular, intravenous, and subcutaneous injection.</p>
          </list-item>
          <list-item>
            <p>Physostigmine is administered intravenously.</p>
          </list-item>
          <list-item>
            <p>Galantamine, donepezil, and rivastigmine are administered orally.</p>
          </list-item>
          <list-item>
            <p>Edrophonium is administered through intramuscular injection.</p>
          </list-item>
          <list-item>
            <p>Pyridostigmine is administered orally.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25378.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of muscarinic agonists can be memorized using the mnemonic "DUMBBELSS."&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Urination</p>
          </list-item>
          <list-item>
            <p>Miosis</p>
          </list-item>
          <list-item>
            <p>Bronchospasm</p>
          </list-item>
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>Excitation of skeletal muscle and CNS</p>
          </list-item>
          <list-item>
            <p>Lacrimation</p>
          </list-item>
          <list-item>
            <p>Sweating</p>
          </list-item>
          <list-item>
            <p>Salivation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25378.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Asthma or Chronic Obstructive Pulmonary Disease (COPD) </bold>
</p>
        <p>COPD is a chronic, inflammatory lung disease that results in airflow obstruction in the lungs. Muscarinic agonists cause bronchoconstriction, increase mucous secretion, and can exacerbate chronic obstructive pulmonary disease (COPD) or asthma. &#x000a0;</p>
        <p>
<bold>Peptic Ulcer </bold>
</p>
        <p>Peptic ulcers occur when acid erodes the protective mucous layer of the stomach and other parts of the digestive tract. Muscarinic agonists can cause an increase in gastric acid secretion and can worsen the complication of peptic ulcers.<xref ref-type="bibr" rid="article-25378.r22">[22]</xref>&#x000a0;</p>
        <p>
<bold>Coronary Vascular Disease </bold>
</p>
        <p>Coronary vascular disease occurs when the blood vessels that supply the heart are damaged. Damaged vessels can build up cholesterol plaque that narrows the coronary arteries resulting in chest pain and shortness of breath.<xref ref-type="bibr" rid="article-25378.r23">[23]</xref>&#x000a0;The decreased blood flow can worsen when taking a muscarinic agonist through the mechanism, as&#x000a0;mentioned above.&#x000a0;</p>
        <p>
<bold>Hyperthyroidism </bold>
</p>
        <p>Hyperthyroidism is a condition where the thyroid gland produces excessive thyroxine hormone. Hyperthyroidism accelerates the body's metabolism resulting in weight loss and irregular heartbeat.<xref ref-type="bibr" rid="article-25378.r24">[24]</xref>&#x000a0;Muscarinic agonists' action on the heart and blood vessels causes bradycardia and hypotension. In response to bradycardia and hypotension, the body release norepinephrine from the sympathetic nerves. Norepinephrine in hyperthyroid patients can induce cardiac arrhythmias.<xref ref-type="bibr" rid="article-25378.r25">[25]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25378.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitor adverse effects and possible signs of contraindications as described above to change medication.&#x000a0;</p>
      </sec>
      <sec id="article-25378.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Organophosphate agents are used for insecticides and work by irreversibly inhibiting acetylcholine esterase. Excess acetylcholine act on muscarinic and nicotinic receptors and present with signs of acetylcholine toxicity. Toxicity characteristically demonstrates overactive parasympathetic stimulation and presents with symptoms of diarrhea, urination, miosis, bronchospasm, bradycardia, excitation of skeletal muscle and CNS, lacrimation, sweating, and salivation.<xref ref-type="bibr" rid="article-25378.r26">[26]</xref><xref ref-type="bibr" rid="article-25378.r27">[27]</xref></p>
        <p>Organophosphate poisoning antidotes are atropine and pralidoxime. Atropine is a muscarinic antagonist, and pralidoxime can regenerate acetylcholinesterase.<xref ref-type="bibr" rid="article-25378.r28">[28]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25378.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patient care is most successful when physicians, nurses, pharmacists, and other healthcare professionals exercise effective teamwork and coordination. Everyone, including the patients, needs to be aware of the possible adverse effects of muscarinic agonists. Physicians need to communicate goals, plans, and adverse effects with the patients and everyone involved in their care. Nurses will also need to familiarize themselves with goals, treatment plans, and adverse effects to inform the physician when there is a noticeable change. Pharmacists can educate the patient on taking the drug, educating them on other possible drug-drug interactions, and keeping the prescriber informed if there are any issues. The patient also needs to notify the physician if adverse effects are developing. Through effective teamwork, managing the adverse effects of muscarinic agonists can be performed. [Level 5]</p>
      </sec>
      <sec id="article-25378.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25378&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25378">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25378/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25378">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25378.s11">
        <title>References</title>
        <ref id="article-25378.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zgourides</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Bethanechol chloride as a suggested adjunct to prolonged in vivo exposure therapy in the treatment of paruresis.</article-title>
            <source>Percept Mot Skills</source>
            <year>1988</year>
            <month>Feb</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>319</fpage>
            <page-range>319-22</page-range>
            <pub-id pub-id-type="pmid">2896331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diokno</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Koppenhoefer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bethanechol chloride in neurogenic bladder dysfunction.</article-title>
            <source>Urology</source>
            <year>1976</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>455</fpage>
            <page-range>455-8</page-range>
            <pub-id pub-id-type="pmid">982732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolton</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>The depolarizing action of acetylcholine or carbachol in intestinal smooth muscle.</article-title>
            <source>J Physiol</source>
            <year>1972</year>
            <month>Feb</month>
            <volume>220</volume>
            <issue>3</issue>
            <fpage>647</fpage>
            <page-range>647-71</page-range>
            <pub-id pub-id-type="pmid">5016040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vivino</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Al-Hashimi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>LeVeque</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Salisbury</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Tran-Johnson</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Muscoplat</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldlust</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj&#x000f6;gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group.</article-title>
            <source>Arch Intern Med</source>
            <year>1999</year>
            <month>Jan</month>
            <day>25</day>
            <volume>159</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-81</page-range>
            <pub-id pub-id-type="pmid">9927101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiseman</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Faulds</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia.</article-title>
            <source>Drugs</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-55</page-range>
            <pub-id pub-id-type="pmid">7705213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fetters</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Methacholine challenge test.</article-title>
            <source>Arch Intern Med</source>
            <year>1984</year>
            <month>May</month>
            <volume>144</volume>
            <issue>5</issue>
            <fpage>938</fpage>
            <page-range>938-40</page-range>
            <pub-id pub-id-type="pmid">6370167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Neely</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sabir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kohli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Neostigmine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29261883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Andrade</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Zafar Gondal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Physostigmine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">31424845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siviero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Minicuci</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bellavista</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mishto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marchegiani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chiamenti</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Benussi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ghidoni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nacmias</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bagnoli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ginestroni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scarpino</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Feraco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gianni</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cruciani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paganelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Di Iorio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scognamiglio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grimaldi</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gabelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sorbi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Binetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crepaldi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Franceschi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.</article-title>
            <source>CNS Drugs</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-76</page-range>
            <pub-id pub-id-type="pmid">20088621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>XC</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2014</year>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>615</fpage>
            <page-range>615-31</page-range>
            <pub-id pub-id-type="pmid">24662102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascuzzi</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>The edrophonium test.</article-title>
            <source>Semin Neurol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-8</page-range>
            <pub-id pub-id-type="pmid">12870109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maggi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mantegazza</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment of myasthenia gravis: focus on pyridostigmine.</article-title>
            <source>Clin Drug Investig</source>
            <year>2011</year>
            <month>Oct</month>
            <day>01</day>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>691</fpage>
            <page-range>691-701</page-range>
            <pub-id pub-id-type="pmid">21815707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Unno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arima</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Matsuyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komori</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Phospholipase C involvement in activation of the muscarinic receptor-operated cationic current in Guinea pig ileal smooth muscle cells.</article-title>
            <source>J Pharmacol Sci</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-13</page-range>
            <pub-id pub-id-type="pmid">15215645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>de Castro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Funk</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Lipski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effects of muscarinic acetylcholine receptor activation on membrane currents and intracellular messengers in medium spiny neurones of the rat striatum.</article-title>
            <source>Eur J Neurosci</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>1219</fpage>
            <page-range>1219-30</page-range>
            <pub-id pub-id-type="pmid">15341594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostrom</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ehlert</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>M2 muscarinic receptor inhibition of agonist-induced cyclic adenosine monophosphate accumulation and relaxation in the guinea pig ileum.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>280</volume>
            <issue>1</issue>
            <fpage>189</fpage>
            <page-range>189-99</page-range>
            <pub-id pub-id-type="pmid">8996196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ethier</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Samant</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Madison</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic receptor reserve for inhibition of cAMP accumulation in bovine trachealis cells.</article-title>
            <source>Am J Physiol</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>270</volume>
            <issue>2 Pt 1</issue>
            <fpage>L199</fpage>
            <page-range>L199-207</page-range>
            <pub-id pub-id-type="pmid">8779988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messer</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>The utility of muscarinic agonists in the treatment of Alzheimer's disease.</article-title>
            <source>J Mol Neurosci</source>
            <year>2002</year>
            <season>Aug-Oct</season>
            <volume>19</volume>
            <issue>1-2</issue>
            <fpage>187</fpage>
            <page-range>187-93</page-range>
            <pub-id pub-id-type="pmid">12212779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avery</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Asthana</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Potential role of muscarinic agonists in Alzheimer's disease.</article-title>
            <source>Drugs Aging</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>450</fpage>
            <page-range>450-9</page-range>
            <pub-id pub-id-type="pmid">9413702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Noma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trautwein</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholine activation of single muscarinic K+ channels in isolated pacemaker cells of the mammalian heart.</article-title>
            <source>Nature</source>
            <year>1983</year>
            <month>May</month>
            <day>19-25</day>
            <volume>303</volume>
            <issue>5914</issue>
            <fpage>250</fpage>
            <page-range>250-3</page-range>
            <pub-id pub-id-type="pmid">6302520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kellogg</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Coey</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin.</article-title>
            <source>J Appl Physiol (1985)</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>629</fpage>
            <page-range>629-32</page-range>
            <pub-id pub-id-type="pmid">15649880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ehlert</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Ostrom</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Subtypes of the muscarinic receptor in smooth muscle.</article-title>
            <source>Life Sci</source>
            <year>1997</year>
            <volume>61</volume>
            <issue>18</issue>
            <fpage>1729</fpage>
            <page-range>1729-40</page-range>
            <pub-id pub-id-type="pmid">9365220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vatier</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[MI cholinergic receptors of gastric secretion: current status].</article-title>
            <source>J Pharmacol</source>
            <year>1985</year>
            <volume>16 Suppl 2</volume>
            <fpage>145</fpage>
            <page-range>145-69</page-range>
            <pub-id pub-id-type="pmid">2867250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cassar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rihal</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Chronic coronary artery disease: diagnosis and management.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>84</volume>
            <issue>12</issue>
            <fpage>1130</fpage>
            <page-range>1130-46</page-range>
            <pub-id pub-id-type="pmid">19955250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mathew</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperthyroidism</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">30725738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Acute hyperthyroidism alters adrenoceptor- and muscarinic receptor-mediated responses in isolated rat renal and femoral arteries.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2004</year>
            <month>Jun</month>
            <day>16</day>
            <volume>493</volume>
            <issue>1-3</issue>
            <fpage>191</fpage>
            <page-range>191-9</page-range>
            <pub-id pub-id-type="pmid">15189782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de la Iglesia</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Effect of amphetamine on the hepatic endoplasmic reticulum of the pregnant rat.</article-title>
            <source>Toxicology</source>
            <year>1977</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">841587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Robb</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Regina</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <chapter-title>Organophosphate Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29261901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25378.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tush</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Anstead</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Pralidoxime continuous infusion in the treatment of organophosphate poisoning.</article-title>
            <source>Ann Pharmacother</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>441</fpage>
            <page-range>441-4</page-range>
            <pub-id pub-id-type="pmid">9101007</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
